Market Performance - The North Exchange 50 Index saw a weekly increase of +0.58% from February 9 to February 13, 2026[3] - The average daily trading volume on the North Exchange was approximately CNY 18.575 billion, with a total trading volume of CNY 92.876 billion and a turnover rate of 16.85% during the same period[4][5] - The overall price-to-earnings (P/E) ratio for the North Exchange was approximately 46.94 times, which is higher than the ChiNext's 45.74 times but lower than the Sci-Tech Innovation Board's 78.61 times[21] Sector Performance - Among the 294 listed companies on the North Exchange, 103 companies had positive weekly growth, with the highest being Aide Technology (+144.72%) and Haiseng Medical (+133.86%)[10] - The media sector experienced a significant increase of +22.6%, while the oil and petrochemical sector saw a decline of -8.7%[10] Financing and Regulatory Measures - The North Exchange introduced a comprehensive package of measures to optimize refinancing, focusing on supporting quality listed companies and innovative small and medium-sized enterprises[40] - Key measures include improving the review process for quality companies, enhancing inclusivity for innovative SMEs, simplifying disclosure requirements, and strengthening regulatory oversight[41] Investment Strategy - The recommended investment strategy for 2026 emphasizes focusing on new productive forces in sectors such as renewable energy, intelligent manufacturing, and emerging consumption industries[27] - A bottom-up approach based on financial metrics is advised, targeting companies with high growth potential and strong R&D investment[27] Risk Factors - Potential risks include lower-than-expected policy support, rapid technological changes, and intensified market competition[3]

Group 1 - The three major indices collectively rose, with the ChiNext Index and the Sci-Tech 50 Index both increasing by over 1%. The total trading volume in the Shanghai and Shenzhen markets reached 2.16 trillion yuan, an increase of 159.7 billion yuan compared to the previous trading day [1] - The computing power industry chain experienced a collective surge, with significant gains in computing power leasing concepts. Major companies like Dazhi Technology and Capital Online saw their stocks hit the daily limit [1] - The Ministry of Industry and Information Technology announced plans to develop national computing power interconnection nodes, aiming to enhance the efficiency and service level of public computing resources and promote high-quality development in the computing power sector [1] Group 2 - The CPO concept saw rapid gains, with leading company Tianfu Communication's stock rising by 11.61% to a historical high of 322 yuan per share, bringing its market capitalization to 250.33 billion yuan [2] - The computing power chip concept also rose in the afternoon, with companies like Chipone Technology experiencing over a 10% increase in stock price [2] - The electric grid equipment sector showed strong performance, with companies like Siyuan Electric and Sifang Co. reaching new highs, while other companies in the sector also saw significant stock price increases [2]

Market Overview - On February 12, the three major indices collectively rose, with the ChiNext Index and the Sci-Tech Innovation 50 Index both increasing by over 1% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.16 trillion yuan, an increase of 159.7 billion yuan compared to the previous trading day [1] Index Performance - Shanghai Composite Index: 4134.02 (+2.03, +0.05%) [2] - Shenzhen Component Index: 14283.00 (+122.06, +0.86%) [2] - ChiNext Index: 1816.15 (+27.93, +1.56%) [2] - CSI 300: 4719.58 (+5.76, +0.12%) [2] - CSI 500: 8423.57 (+97.76, +1.17%) [2] Industry Developments - The Ministry of Industry and Information Technology announced plans to develop national computing power interconnection nodes, aiming to enhance the efficiency and service level of public computing resources [3] - Major domestic internet companies, including Tencent, Alibaba, and Baidu, are increasing efforts to attract users to AI applications, which is expected to significantly boost active user numbers in AI applications [3] - The demand for AI applications is driving growth in the domestic computing power industry chain, presenting key development opportunities [3] Stock Highlights - Tianfu Communication, a leader in the CPO concept, saw its stock rise by 11.61% to 322 yuan per share, reaching a market capitalization of 250.33 billion yuan [3] - Chip companies related to computing power also experienced gains, with Chipone Technology rising over 10% [3] - The liquid cooling server concept showed strong performance, with Chuanrun Co. achieving two consecutive trading limits in four days [3] - The electric grid equipment sector saw collective strength, with companies like Siyuan Electric and Sifang Co. reaching new highs [3] Individual Stock Movements - Double Good Energy, a solar energy company, saw its stock price hit the limit up within 10 minutes, with a total market value of 20.1 billion yuan, following the announcement of three overseas orders for high-efficiency heat exchangers [4] - Newly listed company N Haisheng experienced a maximum increase of 244.94%, triggering a trading halt, with over 300 million yuan in transactions [4]

Trading Activity - The average daily trading volume on the North Exchange decreased by 28.69% to 204.93 billion CNY, down from 287.38 billion CNY in the previous week[5] - The weekly turnover rate for the North Exchange was 19.15%, indicating a slight decline compared to previous weeks[7] Index Performance - The North 50 Index experienced a slight decline of 0.70% during the week, with fluctuations influenced by the weak performance of small-cap stocks[14] - Other indices such as the Sci-Tech 50 and the ChiNext Index saw declines of 5.76% and 3.28% respectively, highlighting a broader market downturn[14] Sector Analysis - Most sectors on the North Exchange reported negative median returns, with the beauty and personal care sector leading with a median increase of 2.32%, while the oil and petrochemical sector had the largest decline at -8.42%[20] - The computer industry had the highest median price-to-earnings (P/E) ratio at 139.57 times, indicating a relatively high valuation compared to other sectors[20] New Listings and Market Activity - There were two new IPOs on the North Exchange during the week, but no new stocks were listed[40] - The overall trading scale of the New Third Board decreased, with the innovative tier and basic tier seeing transaction amounts drop by 15.61% and 25.94% respectively[34] Risk Considerations - There is a noted risk of pullback in North Exchange stocks, particularly as trading volumes have shown signs of contraction, which may lead to further declines in the North 50 Index[42]

Trading Activity - The average daily trading volume on the North Exchange decreased by 28.69% to 204.93 billion CNY, down from 287.38 billion CNY in the previous week[5] - The weekly turnover rate for the North Exchange was 19.15%, indicating a decline in trading activity compared to previous weeks[7] Index Performance - The North 50 Index experienced a slight decline of 0.70% during the week, reflecting significant volatility in the market[14] - Other indices such as the Sci-Tech 50 and the ChiNext Index saw declines of 5.76% and 3.28% respectively, indicating a broader market downturn[14] Sector Analysis - Most sectors on the North Exchange reported negative median returns, with the beauty and personal care sector leading with a median increase of 2.32%, while the oil and petrochemical sector had the largest decline at -8.42%[20] - The computer industry had the highest median price-to-earnings (P/E) ratio at 139.57 times, indicating high valuation compared to other sectors[20] New Listings and Market Activity - There were two new IPOs on the North Exchange during the week, but no new stocks were listed[40] - The overall trading scale of the New Third Board decreased, with the innovative layer and basic layer trading amounts dropping by 15.61% and 25.94% respectively[34] Risk Considerations - There is a noted risk of pullback in North Exchange stocks, particularly as trading volumes have shown signs of contraction, which could lead to further declines in the North 50 Index[42]

Core Viewpoint - Haisheng Medical (920166) has been listed on the Beijing Stock Exchange, focusing on the development, production, and sales of anesthesia and monitoring medical devices, which are widely used in various clinical departments [1][2]. Company Overview - Haisheng Medical is a global provider of comprehensive products in the anesthesia and monitoring medical device sector, with its main business activities centered around the R&D, production, and sales of these medical devices [2]. - The company’s products are extensively applied in departments such as anesthesiology, ICU, and emergency medicine [2]. Shareholding Structure - Prior to the issuance, Huang Haisheng directly held 47.11% of the company's shares, making him the controlling shareholder. His spouse, Wu Xiaoye, holds a 20.60% stake in Lixin Investment, which indirectly controls 7.81% of the company’s shares [2]. - Together, Huang Haisheng and Wu Xiaoye control a total of 54.92% of the company's shares, confirming their status as the actual controllers of Haisheng Medical [2]. Fundraising Details - The total amount raised from this issuance is approximately 142.76 million yuan, with a net amount of about 113.44 million yuan [2]. - The raised funds are intended for upgrading and expanding production of anesthesia and monitoring emergency medical devices, establishing a R&D testing center, and building a marketing service base [2].

Group 1 - The core business of the company focuses on anesthesia and monitoring medical devices, catering to clinical needs in ICU and emergency departments [2] - The company has established a product matrix for anesthesia, monitoring, surgical, and nursing products, mastering 14 core technologies that support its product offerings [2] - The company's main products are widely used in thousands of tertiary hospitals across the country [2] Group 2 - The issuance price of the company's shares is set at 12.64 yuan [2] - The issuance price-to-earnings ratio is 13.99, indicating the valuation of the company in the industry [2] - The subscription rate for the shares is 0.02%, reflecting investor interest in the offering [2]

Group 1 - The core event is the listing ceremony of Zhejiang Haiseng Medical Equipment Co., Ltd. on the Beijing Stock Exchange, scheduled for February 12, 2026, from 09:00 to 09:30, with a live broadcast of the entire event [1][3] - Zhejiang Haiseng Medical Equipment Co., Ltd. was established in 2000 and specializes in the research, production, and sales of anesthesia and monitoring medical devices, serving global clinical needs in various departments such as anesthesia, ICU, and emergency [3] - The company is recognized as one of the early technology-driven manufacturers in China focusing on anesthesia and monitoring medical consumables and equipment, positioning itself as a leading enterprise in this niche market [3] Group 2 - The listing ceremony will include several segments: introduction of guests, speeches by leaders, ringing the listing bell, and a group photo session with guests [3]

Core Viewpoint - The implementation of a unified medical service pricing mechanism in Gansu aims to address the long-standing issues of inconsistent pricing and project naming in healthcare services, enhancing the management of nearly 3,000 medical service price items across the province [1][2]. Group 1: Focus on Children - New nursing guidelines include pricing for "premature infant care" and "newborn care," which will be incorporated into the medical insurance payment system, reimbursed at the standard for Class A projects [2]. - Additional pricing items for children under six years old have been established to incentivize healthcare providers to offer higher quality services to young patients [2]. - The pricing mechanism acknowledges the value of nursing staff's expertise and labor in high-risk premature infant care, reflecting respect for medical professionals [2]. Group 2: Focus on the Elderly - The implementation of the pricing guidelines has significantly improved services for the elderly, introducing fees for home hospital beds, home care services, and palliative care [2]. - These new medical service price items allow elderly individuals with mobility issues to receive professional medical care at home, particularly during end-of-life stages, ensuring comprehensive physical and psychological support [2]. Group 3: Support for Innovation - Adjustments in medical service pricing have facilitated the clinical application of advanced technologies such as invasive brain-machine interface technology and AI-assisted diagnostics [2]. - The introduction of air medical transport projects will enhance the emergency rescue capabilities of hospitals, creating an efficient "air life channel" for the public [2]. Group 4: Overall Impact - The Gansu Provincial Medical Insurance Bureau aims to standardize hospital charges through these pricing adjustments, making healthcare access more convenient and strengthening medical security, ultimately improving the health satisfaction of the populace [3].

Investment Rating - The investment rating for the company is "Buy," indicating an expected relative increase of over 15% in the next 6-12 months compared to relevant market indices [43]. Core Insights - The company, Haiseng Medical, specializes in the research, production, and sales of anesthesia and monitoring medical devices, with a strong market presence in various clinical departments such as anesthesia, ICU, and emergency [2][7]. - The company has demonstrated a solid financial performance with projected revenues of 306 million CNY in 2023, 304 million CNY in 2024, and 345 million CNY in 2025, reflecting year-over-year growth rates of 14.25%, -0.70%, and 13.68% respectively [10][4]. - The company has established itself as a leading player in the domestic market for anesthesia and monitoring medical consumables, with a comprehensive product matrix and a robust sales network covering over 600 top-tier hospitals [35][36]. Summary by Sections Basic Financial Status - The company is expected to achieve revenues of 3.06 billion CNY, 3.04 billion CNY, and 3.45 billion CNY from 2023 to 2025, with corresponding net profits of 780 million CNY, 710 million CNY, and 860 million CNY [10][4]. - The company’s revenue sources are primarily from anesthesia and monitoring medical devices, which together account for over 80% of total revenue [10]. Industry Situation - The medical device industry is one of the fastest-growing sectors globally, with a projected market size of 6,379.6 billion USD by 2028, driven by increasing health demands [20][21]. - The domestic medical device market has rapidly expanded, with a compound annual growth rate of 14.76% from 2017 to 2024, indicating significant growth potential [24]. Company Highlights - Haiseng Medical has competitive advantages in core technologies, product variety, and marketing channels, having developed advanced technologies that exceed industry standards [35][36]. - The company is actively engaged in product innovation and development, collaborating with universities to enhance its technological capabilities [36]. Fundraising Project Investments - The company plans to invest in three main projects through its IPO, including upgrading production facilities, establishing a research and testing center, and building a marketing service base [37][38]. Peer Comparison - Compared to similar companies, Haiseng Medical's revenue is below the average of its peers, but its sales gross margin is positioned in the mid-to-high range of the industry [39][40].